Mutation analysis anticipates dietary requirements in phenylketonuria
Related Experiment Video
Updated: Oct 11, 2026
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
1John F. Kennedy Institute, Glostrup, Denmark. flg@kennedy.dk
Insights
Phenylalanine hydroxylase (PAH) deficiency classification is shifting from clinical to genotype-based predictions. This approach allows for more accurate diagnosis and personalized dietary management of hyperphenylalaninemia.
Area of Science:
- Biochemistry
- Genetics
- Metabolic Disorders
Background:
- Phenylalanine hydroxylase (PAH) deficiency presents a highly variable hyperphenylalaninemia phenotype.
- Autosomal recessive inheritance and extensive allelic heterogeneity (approx. 400 mutations) complicate traditional clinical classification.
- Lack of international guidelines has led to confusion in PAH deficiency methodology and terminology.
Purpose of the Study:
- To summarize progress in correlating PAH mutations with biochemical and metabolic phenotypes.
- To establish a genotype-based classification system for PAH deficiency.
- To develop a predictive model for hyperphenylalaninemia phenotypes based on PAH genotypes.
Main Methods:
- Review of recent advancements in mutation detection methods for the PAH locus.
- Utilizing "functionally hemizygous" patients to classify common and rare mutant alleles.
- Development of a general model to predict the combined phenotypic effects of dual PAH mutations.
Main Results:
- Direct correlation between specific PAH mutations and biochemical/metabolic phenotypes is increasingly established.
- A genotype-based classification system for PAH deficiency is becoming feasible.
- A predictive model for hyperphenylalaninemia phenotypes has been developed.
Conclusions:
- Genotype-based prediction of biochemical phenotypes in newborns with hyperphenylalaninemia is now achievable.
- This genotype-driven approach can refine diagnosis and anticipate dietary needs.
- Emerging evidence indicates genotype influences cognitive development, even after dietary therapy cessation.
Unlabelled:
Phenylalanine hydroxylase (PAH) deficiency is inherited as an autosomal recessive trait and the associated hyperphenylalaninaemia phenotype is highly variable, primarily due to a great allelic heterogeneity at the PAH locus (approximately 400 disease-associated mutations are known). The arbitrary classification of PAH deficiency on the basis of clinical parameters has been complicated by the lack of international guidelines, leading to a wide confusion in both methodology and terminology. Recently, significant improvements in methods for detection of mutations have paved the way for an alternative system for classification of PAH deficiency, which is based solely on PAH genotypes. This paper gives a summary of the recent progress made in establishing a direct correlation between individual PAH mutations and biochemical and metabolic phenotypes, including the use of "functionally hemizygous" patients to classify both common and rare mutant alleles, and a simple and general model to predict the combined phenotypic effect of two mutant PAH alleles.
Conclusion:
Genotype-based prediction of the biochemical phenotype is now feasible in the majority of newborns with hyperphenylalaninemia, which may be useful for refining diagnosis and anticipating dietary requirements. A recent observation suggests that the genotype also determines cognitive development if dietary therapy is discontinued at 6 years of age.
Related Concept Videos
01:20Inborn Errors of Metabolism
01:21Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:29Amino Acid Biosynthetic Pathways
01:27Pharmacogenetics of Drug Metabolism: Overview